Accenture Collaborates with 1910 Genetics to Help Biopharma Companies Transform Drug Discovery with AI
Accenture has invested in 1910 Genetics, a biotech company specializing in AI-driven drug discovery. The collaboration aims to accelerate drug development and reduce costs in the biopharma industry through 1910's proprietary Input-Transform-Output (ITO™) platform. This multi-AI agent system uses federated learning and three proprietary data streams to enable high-precision target identification and molecule design optimization. The partnership combines Accenture's enterprise AI scaling expertise with 1910's technology to transform traditional R&D processes and improve drug discovery efficiency. As part of the agreement, Accenture executives will join 1910's Business and Technology Advisory Boards.
Accenture ha investito in 1910 Genetics, una società biotech specializzata nella scoperta di farmaci guidata dall'AI. La collaborazione mira ad accelerare lo sviluppo di farmaci e a ridurre i costi nel settore biopharma attraverso la piattaforma proprietaria Input-Transform-Output (ITO™) di 1910. Questo sistema multi-agente AI utilizza l'apprendimento federato e tre flussi di dati proprietari per abilitare l'identificazione di obiettivi ad alta precisione e l'ottimizzazione del design delle molecole. La partnership unisce l'esperienza di Accenture nella scalabilità dell'AI aziendale con la tecnologia di 1910 per trasformare i processi di R&D tradizionali e migliorare l'efficienza nella scoperta di farmaci. Come parte dell'accordo, i dirigenti di Accenture si uniranno ai Consigli Consultivi Business e Tecnologico di 1910.
Accenture ha invertido en 1910 Genetics, una empresa biotecnológica especializada en el descubrimiento de fármacos impulsado por inteligencia artificial. La colaboración tiene como objetivo acelerar el desarrollo de medicamentos y reducir costos en la industria biopharma a través de la plataforma Input-Transform-Output (ITO™) de 1910. Este sistema multi-agente de IA utiliza el aprendizaje federado y tres flujos de datos propietarios para permitir la identificación de objetivos de alta precisión y la optimización del diseño de moléculas. La asociación combina la experiencia de Accenture en la escalabilidad de la IA empresarial con la tecnología de 1910 para transformar los procesos de I+D tradicionales y mejorar la eficiencia en el descubrimiento de fármacos. Como parte del acuerdo, los ejecutivos de Accenture se unirán a los Consejos Asesores de Negocios y Tecnología de 1910.
액센츄어는 AI 기반 약물 발견을 전문으로 하는 생명공학 회사 1910 유전자에 투자했습니다. 이번 협업은 1910의 독점 플랫폼인 Input-Transform-Output (ITO™)을 통해 제약 산업에서 약물 개발을 가속화하고 비용을 줄이는 것을 목표로 하고 있습니다. 이 다중 AI 에이전트 시스템은 연합 학습과 세 가지 독점 데이터 스트림을 사용하여 고정밀 목표 식별과 분자 설계 최적화를 가능하게 합니다. 이 파트너십은 전통적인 R&D 프로세스를 혁신하고 약물 발견 효율성을 개선하기 위해 액센츄어의 기업 AI 스케일링 전문성과 1910의 기술을 결합합니다. 계약의 일환으로 액센츄어의 경영진이 1910의 비즈니스 및 기술 자문위원회에 합류할 것입니다.
Accenture a investi dans 1910 Genetics, une société biotechnologique spécialisée dans la découverte de médicaments guidée par l'IA. La collaboration vise à accélérer le développement de médicaments et à réduire les coûts dans l'industrie biopharmaceutique grâce à la plateforme propriétaire Input-Transform-Output (ITO™) de 1910. Ce système multi-agents d'IA utilise l'apprentissage fédéré et trois flux de données propriétaires pour permettre une identification précise des cibles et une optimisation de la conception des molécules. Le partenariat allie l'expertise d'Accenture en matière de mise à l'échelle de l'IA d'entreprise à la technologie de 1910 pour transformer les processus de R&D traditionnels et améliorer l'efficacité de la découverte de médicaments. Dans le cadre de l'accord, des cadres d'Accenture rejoindront les conseils consultatifs en affaires et en technologie de 1910.
Accenture hat in 1910 Genetics investiert, ein Biotech-Unternehmen, das sich auf die KI-gestützte Arzneimittelentdeckung spezialisiert hat. Die Zusammenarbeit zielt darauf ab, die Arzneimittelentwicklung zu beschleunigen und die Kosten in der Biopharma-Branche durch 1910s proprietäre Input-Transform-Output (ITO™) Plattform zu senken. Dieses Multi-AI-Agentensystem nutzt föderiertes Lernen und drei proprietäre Datenströme, um eine hochpräzise Zielidentifizierung und Moleküldesign-Optimierung zu ermöglichen. Die Partnerschaft kombiniert die Expertise von Accenture in der Skalierung von Unternehmens-KI mit der Technologie von 1910, um traditionelle F&E-Prozesse zu transformieren und die Effizienz bei der Arzneimittelentdeckung zu verbessern. Im Rahmen der Vereinbarung werden Führungskräfte von Accenture den Geschäfts- und Technologierat von 1910 beitreten.
- Strategic investment in AI drug discovery technology enhances Accenture's life sciences capabilities
- Partnership provides access to innovative drug development platform that can reduce R&D costs
- Expansion into growing AI-driven pharmaceutical market
- None.
Insights
(Photo: Business Wire)
1910’s proprietary Input-Transform-Output (ITO™) platform is a scalable, end-to-end AI solution designed to deliver better drug candidates with applications across all modalities and therapeutic areas. It is a multi-AI agent system comprising hundreds of models that leverages federated learning alongside three proprietary data streams – computational data, wet lab ground truth biological data and wet lab proxy biological data. The platform helps enable drug discovery teams to achieve high precision target identification, optimize molecule design, and conduct advanced simulation throughout the R&D process. By facilitating data-driven decision making, it can increase the probability of clinical success, while shortening experimental iteration cycles and reducing the overall cost of drug development.
“Taking an AI-driven approach is essential in order to reinvent the drug discovery and development process,” said Tom Lounibos, global lead of Accenture Ventures. “Collaborating with 1910 Genetics allows us to integrate our AI expertise with their innovative technology and deliver solutions that can transform drug discovery and improve patient outcomes.”
Accenture’s expertise in scaling AI solutions across enterprises can help biopharma companies smoothly integrate 1910’s AI platform into their existing pipelines. Together, Accenture and 1910 will combine their experience and expertise to help drive breakthroughs in therapeutic development, improve the efficiency of drug discovery, and drive innovation for biopharma companies.
Petra Jantzer, PhD, a senior managing director and global lead of Life Sciences at Accenture, added, “We look forward to joining up our diverse experience in implementing generative AI projects across enterprises and deep expertise in the life sciences sector with 1910 Genetics and its holistic, comprehensive AI platform. Our investment and collaboration support our vision for our biopharma clients to implement tech-enabled drug discovery, automating processes, breaking down silos and increasing productivity.”
“In our discussions with biopharma companies, the desire for AI transformation of their traditional R&D processes is evident,” said Jen Nwankwo, PhD, founder and CEO of 1910 Genetics. “It’s also clear that 1910’s end-to-end AI platform – from in silico to the wet lab and back – addresses the challenges that biopharma companies face with point solutions. By collaborating with Accenture, we aim to bring 1910’s AI platform to biopharma companies as an enterprise-wide horizontal infrastructure that breaks down barriers in data, model, and computing power to accelerate the discovery and development of both small and large molecule therapeutics across all therapeutic areas.”
In conjunction with this announcement, Dr. Petra Jantzer and Tom Lounibos will join the Business Advisory Board of 1910, and Dr. Kailash Swarna, a managing director in Life Sciences at Accenture, and Dr. Cecil Lynch, Biomedical Informatics lead at Accenture, will join the Technology Advisory Board of 1910.
1910 will also join Accenture Ventures’ Project Spotlight, an engagement and investment program for startup companies that create or apply disruptive enterprise technologies.
Terms of the investment were not disclosed.
About Accenture
Accenture is a leading global professional services company that helps the world’s leading organizations build their digital core, optimize their operations, accelerate revenue growth and enhance services—creating tangible value at speed and scale. We are a talent- and innovation-led company with approximately 774,000 people serving clients in more than 120 countries. Technology is at the core of change today, and we are one of the world’s leaders in helping drive that change, with strong ecosystem relationships. We combine our strength in technology and leadership in cloud, data and AI with unmatched industry experience, functional expertise and global delivery capability. Our broad range of services, solutions and assets across Strategy & Consulting, Technology, Operations, Industry X and Song, together with our culture of shared success and commitment to creating 360° value, enable us to help our clients reinvent and build trusted, lasting relationships. We measure our success by the 360° value we create for our clients, each other, our shareholders, partners and communities. Visit us at www.accenture.com.
About 1910 Genetics
1910 Genetics is the only biotechnology company advancing small and large molecule drug discovery with a multimodal AI platform powered by laboratory automation. We integrate AI that leverages federated learning alongside three proprietary data streams – computational data, wet lab proxy biological data, and wet lab ground truth biological data – to deliver novel drug candidates and software solutions to leading biopharma and tech partners, and advance our internal pipeline for neurological, autoimmune diseases, and cancer. We recently established a commercial partnership with Microsoft to bring our ITO™ platform to biopharma companies at scale.
1910 was launched in 2021 with a combined seed and Series A funding of
Copyright ©2024 Accenture. All rights reserved. Accenture and its logo are registered trademarks of Accenture.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241031947751/en/
Marchell Gillis
Accenture
+1 678-657-7515
marchell.gillis@accenture.com
Keerthi Goutham
Accenture
Keerthi.goutham@accenture.com
1910 Genetics PR
media@1910Genetics.com
Source: 1910 Genetics
FAQ
What is the purpose of Accenture's investment in 1910 Genetics?
How does 1910 Genetics' ITO platform work in drug discovery?
What role will Accenture play in the collaboration with 1910 Genetics?
